Effects of Matrix Age on Protein Binding Results Extracted with a Phospholipid Removal Plate and Analyzed using MFLC-MS/MS 

Here we demonstrate the routine use of microflow LC-MS/MS in a bioanalytical lab to measure the binding of drugs to plasma proteins.  The unbound drug concentration impacts the efficacy and toxicity of a pharmaceutical in vivo, and interactions between plasma proteins and the drug control its systemic effects; hence, research on factors that impact the degree of protein binding are relevant to clinicians, pharmaceutical developers and academics alike. The data show that the protein binding effects of plasma/serum age and the plasma anti-coagulant when propranolol is spiked in plasma/serum and the percent protein binding is determined.

Topics Covered:

  • Introduction to MFLC-MS/MS
  • Use of phospholipid removal filter plates to minimize MS ion suppression in human serum and plasma samples
  • Protein binding impact of plasma/serum age and plasma anti-coagulants
  • Evaluation of MFLC-MS/MS for routine use in bioanalysis

Who should attend:

  • Clinical scientists
  • Biomedical researchers
  • Pharmaceutical scientists
  • Bioanalytical scientists

Panelist’s biography:

Shane Needham, Ph.D.
Laboratory Director
Alturas Analytics, Inc.

Dr. Shane Needham received his B.S. degree in Chemistry from Washington State University and his Ph.D. in Chemistry from the University of Rhode Island.  Dr. Needham is Laboratory Director of the LC-MS/MS bioanalytical CRO Alturas Analytics, Inc.  Currently, Dr. Needham’s work is focused on the development and validation of assays for the determination of therapeutic agents and biomarkers from biological matrices.  His laboratory has been a leader in the area of dried blood spot (DBS) analysis and microflow HPLC-MS/MS to support DMPK research.  He previously worked in the bioanalytical MS group for Pfizer in Groton, Connecticut.  Dr. Needham has over 100 publications and presentations in the area of LC/MS.